EMA Withdrawn: Truberzi (eluxadoline) — Allergan Pharmaceuticals International Limited

View source ↗

Summary

The EMA has withdrawn Truberzi (eluxadoline) from the market for irritable bowel syndrome with diarrhea.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome with Diarrhea

Drugs mentioned

• Truberzi (eluxadoline)

Snippet

Status: Withdrawn. Therapeutic area: Irritable Bowel Syndrome;Diarrhea. MAH: Allergan Pharmaceuticals International Limited. Decision date: 12/02/2020